The hematologic malignancy program at the Duke Cancer Institute combines state-of-the-art, compassionate medical care with innovative science to improve outcomes for patients battling leukemias, lymphomas, myelomas, and other blood- and lymphoid-related cancers, including many rare cancers.
The most common types of adult leukemia are acute myeloid leukemia and chronic lymphocytic leukemia. Five-year survival rates for leukemia patients vary depending on risk factors but have generally improved since the 1970s with many patients having long-term survival.
A highly experienced team of caregivers provides individualized, hands-on medical attention to each of the nearly 1,000 patients we see each year. The multidisciplinary team includes physicians, nurse practitioners, physician assistants, physical therapists, social workers, pharmacists, nutritionists, and financial advisors.
This team works closely together to provide the best care possible to meet the individual needs of each patient.
Our nationally reputed medical oncologists, surgeons, radiation oncologists, and stem cell and marrow transplantation specialists work together to plan a comprehensive treatment strategy for each patient, drawing on the most effective therapies -- including many that have been developed and refined right here at the Duke Cancer Institute.
For patients who have recurrent cancers, we provide a seamless transition to Duke's internationally renowned adult bone marrow and stem cell transplant team.
The Duke Cancer Institute offers specialized programs to meet the unique, individual needs of our patients:
There is much research being conducted at the Duke Cancer Institute and throughout the world in laboratories and clinical trials to find new therapies for this leukemias, lymphomas, and myelomas. Much progress has already been made, and the future is bright.
Our patients have access to some of the latest developments in treatment therapies through clinical trials.
Learn how to make an appointment at the Duke Cancer Institute.